Alnylam recibe la aprobación de la Comisión Europea para AMVUTTRA® (vutrisiran) en el tratamiento de la amiloidosis ATTR con miocardiopatía
1. Alnylam's AMVUTTRA® approved for hereditary ATTR-CM treatment in Europe. 2. The approval follows recent authorizations in the U.S. and Brazil. 3. HELIOS-B study showed 36% all-cause mortality reduction with treatment. 4. Treatment offers functional capacity and quality of life preservation. 5. AMVUTTRA® is the first ARNi therapy authorized for this indication.